Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.

New horizons in tumor microenvironment biology: challenges and opportunities

Open access

Abstract

The tumor microenvironment (TME) is being increasingly recognized as a key factor in multiple stages of disease progression, particularly local resistance, immune-escaping, and distant metastasis, thereby substantially impacting the future development of frontline interventions in clinical oncology. An appropriate understanding of the TME promotes evaluation and selection of candidate agents to control malignancies at both the primary sites as well as the metastatic settings. This review presents a timely outline of research advances in TME biology and highlights the prospect of targeting the TME as a critical strategy to overcome acquired resistance, prevent metastasis, and improve therapeutic efficacy. As benign cells in TME niches actively modulate response of cancer cells to a broad range of standard chemotherapies and targeted agents, cancer-oriented therapeutics should be combined with TME-targeting treatments to achieve optimal clinical outcomes. Overall, a body of updated information is delivered to summarize recently emerging and rapidly progressing aspects of TME studies, and to provide a significant guideline for prospective development of personalized medicine, with the long term aim of providing a cure for cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12916-015-0278-7

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cancer develops in a complex and dynamic TME, which exerts profound impacts to disease progression. Cancer cells are in close relationship with diverse non-cancer cell types within the TME, forming a functional nexus that facilitates tumor initiation, survival, and exacerbation. Cytotoxicity generated by treatments including chemotherapy, radiation, and targeted therapy eliminates many malignant cells within the cancer cell population; however, surviving cells are frequently retained in specific TME niches. Such protection minimizes the sensitivity to anti-cancer agents and generates resistant subclones through distinct mechanisms, prominently through acquired resistance conferred by a large body of soluble factors released from damaged or remodeled stroma. Alternatively, BMDCs, including MSCs and Tregs, mediate immunomodulation and prevent inflammation by restraining the activity of cytotoxic T cells, correlating with poor prognosis. Either acquired resistance or immunosurveillance evasion promotes cancer cell survival and subsequent expansion, allowing development of more advanced phenotypes, including tumor relapse, distant metastasis, and therapeutic failure, eventually causing high mortality in clinical settings. CAF, Carcinoma-associated fibroblast; MSC, Mesenchymal stem cell; BMDC, Bone marrow-derived cell; Treg cell, Regulatory T cell; EC, Endothelial cell; ECM, Extracellular matrix; TAM, Tumor-associated macrophage.
Figure 1 Cancer develops in a complex and dynamic TME, which exerts profound impacts to disease progression. Cancer cells are in close relationship with diverse non-cancer cell types within the TME, forming a functional nexus that facilitates tumor initiation, survival, and exacerbation. Cytotoxicity generated by treatments including chemotherapy, radiation, and targeted therapy eliminates many malignant cells within the cancer cell population; however, surviving cells are frequently retained in specific TME niches. Such protection minimizes the sensitivity to anti-cancer agents and generates resistant subclones through distinct mechanisms, prominently through acquired resistance conferred by a large body of soluble factors released from damaged or remodeled stroma. Alternatively, BMDCs, including MSCs and Tregs, mediate immunomodulation and prevent inflammation by restraining the activity of cytotoxic T cells, correlating with poor prognosis. Either acquired resistance or immunosurveillance evasion promotes cancer cell survival and subsequent expansion, allowing development of more advanced phenotypes, including tumor relapse, distant metastasis, and therapeutic failure, eventually causing high mortality in clinical settings. CAF, Carcinoma-associated fibroblast; MSC, Mesenchymal stem cell; BMDC, Bone marrow-derived cell; Treg cell, Regulatory T cell; EC, Endothelial cell; ECM, Extracellular matrix; TAM, Tumor-associated macrophage.CC BY · PubMed Central
Figure 2 Illustrative models for the preclinical evaluation of novel anticancer regimes that incorporate TME-targeting agents. (A) Route 1 (singular), tumors develop in transgenic mice before the preclinical administration of chemotherapy or targeted therapy is applied as a singular agent. Dramatic cancer resistance is observed in such a therapeutic approach, with only limited efficacy available. (B) Route 2 (combinational), in contrast to route 1, an updated regime incorporating the novel agents (small molecule inhibitor or monoclonal antibodies) into the treatment program, which allows targeting both the tumor and TME. Significant disease regression follows after several cycles of the novel treatments, with much higher preclinical index achieved. (C) Route 3 (singular), tumors develop in the immunocompetent (wild type) mice xenografted with cancer cells and stromal cells from the same genetic and/or strain background as the host. Upon exposure to treatments as in Route A, a low outcome is observed. (D) Route 4 (combinational), tumors develop in the xenograft mice as in C, harboring implanted cancer and stromal components. Once receiving the same treatments as in Route B, animals present significantly improved therapeutic efficacy. (Note, in routes C and D, the preclinical paradigm in prospective trials exclude PDX, although it is a highly recommended model for many cancer studies).
Figure 2 Illustrative models for the preclinical evaluation of novel anticancer regimes that incorporate TME-targeting agents. (A) Route 1 (singular), tumors develop in transgenic mice before the preclinical administration of chemotherapy or targeted therapy is applied as a singular agent. Dramatic cancer resistance is observed in such a therapeutic approach, with only limited efficacy available. (B) Route 2 (combinational), in contrast to route 1, an updated regime incorporating the novel agents (small molecule inhibitor or monoclonal antibodies) into the treatment program, which allows targeting both the tumor and TME. Significant disease regression follows after several cycles of the novel treatments, with much higher preclinical index achieved. (C) Route 3 (singular), tumors develop in the immunocompetent (wild type) mice xenografted with cancer cells and stromal cells from the same genetic and/or strain background as the host. Upon exposure to treatments as in Route A, a low outcome is observed. (D) Route 4 (combinational), tumors develop in the xenograft mice as in C, harboring implanted cancer and stromal components. Once receiving the same treatments as in Route B, animals present significantly improved therapeutic efficacy. (Note, in routes C and D, the preclinical paradigm in prospective trials exclude PDX, although it is a highly recommended model for many cancer studies).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 105 references

Research works printed but not linked: 1

  1. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Canc Metastasis Rev. 1989;8:98–101.

Cited by

See all 723

Metadata

Authors
Chen, F., Zhuang, X., Lin, L., Yu, P., Wang, Y., Shi, Y., Hu, G., & Sun, Y.
Affiliations
Shanghai Jiao Tong University (CN)
Corresponding author
Sun, Yu
Venue
BMC Medicine
Published
2015-03-05
Volume
13
Issue
1
Pages
45-45
ISSN
1741-7015 (ISSN-L)
OpenAlex
W2127686099
Cited by
704
References
105
Citations by year
2026: 24 · 2025: 49 · 2024: 63 · 2023: 76 · 2022: 79 · 2021: 98 · 2020: 83 · 2019: 65 · 2018: 64 · 2017: 47 · 2016: 37 · 2015: 19
FWCI
5.99
Type
journal article
Language
en
Open access
Locations
  • BMC Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Defense (PC111703)
  • University of Washington (WA 98195)
  • National Natural Science Foundation of China (81330046, 81472709, 31371409)
  • Chinese Academy of Sciences (215123, XDA01040107, XDA01040110)
  • Soochow University (215123)
  • Shanghai Rising-Star Program
  • Directorate for Biological Sciences
  • School of Medicine, Shanghai Jiao Tong University
  • Congressionally Directed Medical Research Programs
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
tumor microenvironment, acquired drug resistance, immune evasion, metastasis, cancer immunotherapy, chemoresistance, personalized medicine, cancer therapy
MeSH terms
Humans, Medical Oncology, Neoplasms, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New horizons in tumor microenvironment biology: challenges and opportunities. https://app.cochat.ai/papers/10.1186/s12916-015-0278-7
The paper
Chen, F., Zhuang, X., Lin, L., Yu, P., Wang, Y., Shi, Y., Hu, G., & Sun, Y. (2015). New horizons in tumor microenvironment biology: challenges and opportunities. BMC Medicine. https://doi.org/10.1186/s12916-015-0278-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.